EHA Library - The official digital education library of European Hematology Association (EHA)

DETECTION OF JAK2 EXON 12 MUTATIONS BY HETERODUPLEX ANALYSIS AND PYROSEQUENCING
Author(s): ,
Tatiana Subbotina
Affiliations:
Department of Medical Biology,Siberian Federal University,Krasnoyarsk,Russian Federation;Krasnoyarsk branch of the Federal State budgetary Institution «Hematology Research Center» Department of Health,Krasnoyarsk,Russian Federation
,
Elena Dunaeva
Affiliations:
Federal Budget Institute of Science «Central Research Institute for Epidemiology»,Moscow,Russian Federation
,
Konstantin Mironov
Affiliations:
Federal Budget Institute of Science «Central Research Institute for Epidemiology»,Moscow,Russian Federation
,
Anastasiya Kharsekina
Affiliations:
Department of Medical Biology,Siberian Federal University,Krasnoyarsk,Russian Federation
,
Evgeny Vasiyliev
Affiliations:
Krasnoyarsk regional hospital,Krasnoyarsk,Russian Federation;Krasnoyarsk branch of the Federal State budgetary Institution «Hematology Research Center» Department of Health,Krasnoyarsk,Russian Federation
,
Mikhail Mikhalev
Affiliations:
Municipal Budget Health Service Institution «City Clinical Hospital № 7»,Krasnoyarsk,Russian Federation;Krasnoyarsk branch of the Federal State budgetary Institution «Hematology Research Center» Department of Health,Krasnoyarsk,Russian Federation
,
Marina Osadchaya
Affiliations:
Krasnoyarsk Territory Department of Health Regional state budget health facility «Krasnoyarsk interdistrict clinic №1»,Krasnoyarsk,Russian Federation
,
Maria Smelyanskaya
Affiliations:
Krasnoyarsk regional hospital,Krasnoyarsk,Russian Federation
,
Vladimir Khorzhevskyi
Affiliations:
Krasnoyarsk State Regional Bureau of Pathology,Krasnoyarsk,Russian Federation;Krasnoyarsk branch of the Federal State budgetary Institution «Hematology Research Center» Department of Health,Krasnoyarsk,Russian Federation
,
Igor Olkhovskiy
Affiliations:
Krasnoyarsk branch of the Federal State budgetary Institution «Hematology Research Center» Department of Health,Krasnoyarsk,Russian Federation;Krasnoyask Scientific Center of the Siberian Branch of the Russian Academy of Sciences,Krasnoyarsk,Russian Federation
German Shipulin
Affiliations:
Federal Budget Institute of Science «Central Research Institute for Epidemiology»,Moscow,Russian Federation
(Abstract release date: 05/18/17) EHA Library. Subbotina T. 05/18/17; 182749; PB2035
Dr. Tatiana Subbotina
Dr. Tatiana Subbotina
Contributions
Abstract

Abstract: PB2035

Type: Publication Only

Background
Somatic mutations in codons 533-547 of JAK2 exon 12 are highly specific to confirm the diagnosis of polycythemia vera (PV). We have previously proposed techniques for the detection and quantification of JAK2 exon 12 allele burden using a pyrosequencing method (Subbotina T et al, Haematologica 2014). However, due to the high cost of sequencing, developing a two-stage algorithm for detect mutations in JAK2 exon 12 using inexpensive screening is of immediate practically necessity.

Aims

The aim of this study was to demonstrate the feasibility of using heteroduplex analysis with separation of the PCR product by electrophoresis on non-denaturing PAGE as the preliminary screening test for detection of JAK2 exon 12 mutations.

Methods
274 patients with PV or unclear erythrocytosis and with a low JAK2V617F allele burden or unmutated JAK2V617 (51 women, mean age 52.2±15.7 years and 223 men, mean age 43.6±15.6 years) were included in this study. The informed consents from these patients were obtained. The PCR with the additional stage of formation heteroduplexes was performed using the Real-time PCR kit (Syntol, Russia) and CFX 96 Real Time System (Biorad, USA). PCR products were analyzed by electrophoresis in 8% PAGE. The presence of the mutations was identified and confirmed by pyrosequencing method with PyroMark Q24 (Qiagen, Germany). To verify the presence of mutations, the DNA sequences extracted from the clinical samples were cloned into pGem-T vector using standard protocol («Promega», USA), and obtained clones were sequenced using reagents and equipment of the «Applied Biosystems» (USA). JAK2 exon 12 varianceMUT was calculated as a measure of relative changes in allele burden between the baseline and follow-up sample (Theocharides A et al, Haematologica, 2008).

Results

We detected JAK2 exon 12 mutation in five out 274 patients. The results of electrophoresis on non-denaturing PAGE are reported in Figure 1. The type of №1-5 patient mutations was determined by pyrosequencing: N542-E543del (c.1624_1629delAATGAA); I540-E543delinsKK (с.1619_1627 TCAgAAATgK (c.1622_1627delGAAATG) and p.H538_K539>L (c.1612_1616CACAA>TT). These mutations have been already described. Main characteristics of 5 patients with JAK2 exon 12-mutated PV are reported in Table 1. The PV diagnosis of №1, 2, 3 and 5 patients was confirmed by bone marrow trephine biopsies histological examination. All five patients with JAK2 exon 12-mutated PV have an increased number of red blood cells, along with an accompanying increase in the concentration of hemoglobin and hematocrit level in the peripheral blood. Some of them had increase number of leukocytes and platelets in the disease dynamics. №1-4 patients was treated phlebotomy only and did not received any cytoreductive treatment to date. Patient №5 receives hydroxyurea (HU). Importantly, two out five patients with JAK2 exon 12-mutated PV also have a mutation JAK2V617 (<1%). JAK2 exon 12 allele burden in sample from №1 patient is significantly increased in the disease dynamics.

Conclusion

The proposed variant of the heteroduplex analysis with separation of the PCR product by electrophoresis on non-denaturing PAGE can be recommended for use as the preliminary screening test which is carried out before the confirming pyrosequencing. The two-stage approach allows to optimize the algorithm of the JAK2 exon 12 mutation detection and to improve the efficiency of testing for patients suspected of having PV in whom a JAK2V617F mutation is not detected or detected in a low allele burden. In five out 274 patients we detected JAK2 exon 12 mutation and confirmed the diagnosis of PV.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Myeloproliferative disorder

Abstract: PB2035

Type: Publication Only

Background
Somatic mutations in codons 533-547 of JAK2 exon 12 are highly specific to confirm the diagnosis of polycythemia vera (PV). We have previously proposed techniques for the detection and quantification of JAK2 exon 12 allele burden using a pyrosequencing method (Subbotina T et al, Haematologica 2014). However, due to the high cost of sequencing, developing a two-stage algorithm for detect mutations in JAK2 exon 12 using inexpensive screening is of immediate practically necessity.

Aims

The aim of this study was to demonstrate the feasibility of using heteroduplex analysis with separation of the PCR product by electrophoresis on non-denaturing PAGE as the preliminary screening test for detection of JAK2 exon 12 mutations.

Methods
274 patients with PV or unclear erythrocytosis and with a low JAK2V617F allele burden or unmutated JAK2V617 (51 women, mean age 52.2±15.7 years and 223 men, mean age 43.6±15.6 years) were included in this study. The informed consents from these patients were obtained. The PCR with the additional stage of formation heteroduplexes was performed using the Real-time PCR kit (Syntol, Russia) and CFX 96 Real Time System (Biorad, USA). PCR products were analyzed by electrophoresis in 8% PAGE. The presence of the mutations was identified and confirmed by pyrosequencing method with PyroMark Q24 (Qiagen, Germany). To verify the presence of mutations, the DNA sequences extracted from the clinical samples were cloned into pGem-T vector using standard protocol («Promega», USA), and obtained clones were sequenced using reagents and equipment of the «Applied Biosystems» (USA). JAK2 exon 12 varianceMUT was calculated as a measure of relative changes in allele burden between the baseline and follow-up sample (Theocharides A et al, Haematologica, 2008).

Results

We detected JAK2 exon 12 mutation in five out 274 patients. The results of electrophoresis on non-denaturing PAGE are reported in Figure 1. The type of №1-5 patient mutations was determined by pyrosequencing: N542-E543del (c.1624_1629delAATGAA); I540-E543delinsKK (с.1619_1627 TCAgAAATgK (c.1622_1627delGAAATG) and p.H538_K539>L (c.1612_1616CACAA>TT). These mutations have been already described. Main characteristics of 5 patients with JAK2 exon 12-mutated PV are reported in Table 1. The PV diagnosis of №1, 2, 3 and 5 patients was confirmed by bone marrow trephine biopsies histological examination. All five patients with JAK2 exon 12-mutated PV have an increased number of red blood cells, along with an accompanying increase in the concentration of hemoglobin and hematocrit level in the peripheral blood. Some of them had increase number of leukocytes and platelets in the disease dynamics. №1-4 patients was treated phlebotomy only and did not received any cytoreductive treatment to date. Patient №5 receives hydroxyurea (HU). Importantly, two out five patients with JAK2 exon 12-mutated PV also have a mutation JAK2V617 (<1%). JAK2 exon 12 allele burden in sample from №1 patient is significantly increased in the disease dynamics.

Conclusion

The proposed variant of the heteroduplex analysis with separation of the PCR product by electrophoresis on non-denaturing PAGE can be recommended for use as the preliminary screening test which is carried out before the confirming pyrosequencing. The two-stage approach allows to optimize the algorithm of the JAK2 exon 12 mutation detection and to improve the efficiency of testing for patients suspected of having PV in whom a JAK2V617F mutation is not detected or detected in a low allele burden. In five out 274 patients we detected JAK2 exon 12 mutation and confirmed the diagnosis of PV.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Myeloproliferative disorder

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies